PCSK9 Inhibitors: Treating the Right Patients in Daily Practice

Peta King, Stephen J. Nicholls

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

PURPOSE OF REVIEW: Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) have emerged as a novel approach to low-density lipoprotein cholesterol (LDL-C) lowering. The potential role of PCSK9 inhibitors in clinical practice will be reviewed. RECENT FINDINGS: Clinical trials have demonstrated that PCSK9 inhibitors produce robust LDL-C lowering when administered either as monotherapy or in combination with statins. This provides the opportunity to achieve effective lipid lowering in familial hypercholesterolemia, patients with either established atherosclerotic cardiovascular disease or high risk primary prevention and an important opportunity to treat patients with statin intolerance. The findings from plaque imaging and patients with established atherosclerotic cardiovascular disease suggest that PCSK9 inhibition has favorable outcomes beyond improving lipid profiles, which has the opportunity to expand their use. PCSK9 inhibitors represent a new approach to achieving effective cardiovascular risk reduction in a broader number of patients. How these agents will be taken up in clinical practice remains to be determined.
LanguageEnglish
JournalCurrent Cardiology Reports
Volume19
Issue number8
DOIs
Publication statusPublished - 1 Aug 2017

Keywords

  • Cardiovascular disease
  • Lipids
  • PCSK9
  • Risk factors

Cite this

King, Peta ; Nicholls, Stephen J. / PCSK9 Inhibitors: Treating the Right Patients in Daily Practice. In: Current Cardiology Reports. 2017 ; Vol. 19, No. 8.
@article{8a1c022ff41c4902903a7439165f2409,
title = "PCSK9 Inhibitors: Treating the Right Patients in Daily Practice",
abstract = "PURPOSE OF REVIEW: Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) have emerged as a novel approach to low-density lipoprotein cholesterol (LDL-C) lowering. The potential role of PCSK9 inhibitors in clinical practice will be reviewed. RECENT FINDINGS: Clinical trials have demonstrated that PCSK9 inhibitors produce robust LDL-C lowering when administered either as monotherapy or in combination with statins. This provides the opportunity to achieve effective lipid lowering in familial hypercholesterolemia, patients with either established atherosclerotic cardiovascular disease or high risk primary prevention and an important opportunity to treat patients with statin intolerance. The findings from plaque imaging and patients with established atherosclerotic cardiovascular disease suggest that PCSK9 inhibition has favorable outcomes beyond improving lipid profiles, which has the opportunity to expand their use. PCSK9 inhibitors represent a new approach to achieving effective cardiovascular risk reduction in a broader number of patients. How these agents will be taken up in clinical practice remains to be determined.",
keywords = "Cardiovascular disease, Lipids, PCSK9, Risk factors",
author = "Peta King and Nicholls, {Stephen J.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1007/s11886-017-0882-6",
language = "English",
volume = "19",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "8",

}

PCSK9 Inhibitors: Treating the Right Patients in Daily Practice. / King, Peta; Nicholls, Stephen J.

In: Current Cardiology Reports, Vol. 19, No. 8, 01.08.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - PCSK9 Inhibitors: Treating the Right Patients in Daily Practice

AU - King, Peta

AU - Nicholls, Stephen J.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - PURPOSE OF REVIEW: Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) have emerged as a novel approach to low-density lipoprotein cholesterol (LDL-C) lowering. The potential role of PCSK9 inhibitors in clinical practice will be reviewed. RECENT FINDINGS: Clinical trials have demonstrated that PCSK9 inhibitors produce robust LDL-C lowering when administered either as monotherapy or in combination with statins. This provides the opportunity to achieve effective lipid lowering in familial hypercholesterolemia, patients with either established atherosclerotic cardiovascular disease or high risk primary prevention and an important opportunity to treat patients with statin intolerance. The findings from plaque imaging and patients with established atherosclerotic cardiovascular disease suggest that PCSK9 inhibition has favorable outcomes beyond improving lipid profiles, which has the opportunity to expand their use. PCSK9 inhibitors represent a new approach to achieving effective cardiovascular risk reduction in a broader number of patients. How these agents will be taken up in clinical practice remains to be determined.

AB - PURPOSE OF REVIEW: Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) have emerged as a novel approach to low-density lipoprotein cholesterol (LDL-C) lowering. The potential role of PCSK9 inhibitors in clinical practice will be reviewed. RECENT FINDINGS: Clinical trials have demonstrated that PCSK9 inhibitors produce robust LDL-C lowering when administered either as monotherapy or in combination with statins. This provides the opportunity to achieve effective lipid lowering in familial hypercholesterolemia, patients with either established atherosclerotic cardiovascular disease or high risk primary prevention and an important opportunity to treat patients with statin intolerance. The findings from plaque imaging and patients with established atherosclerotic cardiovascular disease suggest that PCSK9 inhibition has favorable outcomes beyond improving lipid profiles, which has the opportunity to expand their use. PCSK9 inhibitors represent a new approach to achieving effective cardiovascular risk reduction in a broader number of patients. How these agents will be taken up in clinical practice remains to be determined.

KW - Cardiovascular disease

KW - Lipids

KW - PCSK9

KW - Risk factors

U2 - 10.1007/s11886-017-0882-6

DO - 10.1007/s11886-017-0882-6

M3 - Article

VL - 19

JO - Current Cardiology Reports

T2 - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 8

ER -